MedTrace Logo

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

NCT02960880 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99999

Last updated 2017-12-26

No results posted yet for this study

Summary

The aim of this study is to assess the real world comparative effectiveness of Rivaroxaban prescribed in non-valvular atrial fibrillation (NVAF) routine care patients in Germany.

Conditions

Interventions

DRUG

Rivaroxaban (Xarelto, BAY597939)

15mg, 20mg

DRUG

Phenprocoumon (branded and generics)

Individually adjusted dose

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-15
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Germany

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02960880 on ClinicalTrials.gov